Natco Pharma has reported results for third quarter ended December 31, 2014.
The company has registered a fall of 48.77% in its net profit after tax at Rs 16.61 crore for the quarter under review as compared to Rs 32.42 crore for the same quarter in the previous year. Total income of the company has decreased 0.68% at Rs 174.08 crore for Q3FY15 as compared Rs 175.28 crore for the corresponding quarter previous year.
On the consolidated basis the company’s net profit after tax, share of minority interest and share of profit/(loss) of associates declined 52.01% to Rs 14.34 crore for the Q3 FY15 as compared to Rs 29.88 crore in Q3 FY14. The total income decreased 0.89% to Rs 202.80 crore in the quarter under review as compared to Rs 204.63 crore in the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.55 |
| Dr. Reddys Lab | 1238.10 |
| Cipla | 1239.20 |
| Zydus Lifesciences | 942.70 |
| Lupin | 2325.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: